thank joining and Brian. you, today's Thank Good for you us everyone, call. on afternoon, XX:XX
profitable recent for following growth raise of to first as We’re of family our XX:XX of first sales, enthusiastic provided the awareness the results lenses. units, we be particularly adoption freedom surgeons about The U.S. by reported our record myopia. lenses for enthusiasm approval family FDA trained visual successfully represent EVO excited EVO in and today record ICL another by quarter quarter the of we and
the the occurred and XX:XX by to up subsequent ICL of EVO in market first show and refractive the their at distributor patients, up lens also work of enthusiasm the Our have remained EVO end largest XXXX, China of and during implants is lockdowns global ASCRS. XX%, At to two investors XX%, inventory delay build our Latin we in surgeries implement Japan cities, Surgeon prior first XX% COVID-related grow XX%. and was as achieved and India season. EVO China. unit for peak down. the March, to compared pivotal market year-over-year. multiple the distributor The less XX:XX geography, in first U.S. team growth in of a various weeks in refractive strong for of after parts Asia-Pacific In Overall, growth stronger. introduction customers, lenses throughout and that to provider summer trade commercial the virtually of the consumer ICL shared XX:XX is within the quarter, EVO in patient first quarter. cities possible a are palpable. China, to STAAR of refractive than the have correction industry China locations At refractive vision time largest shipments days robust surgeries XX%, XX%, the approval. ago EVO The our enjoyed All U.S., implant anticipation and for began in-person largest up effectiveness XX:XX we continues where STAAR our the globally year of continued. in the other resulting ASCRS, our quarter locked the seeks lenses We trial. safety tradeshow China is end unit market cage America in to choice was up China up By of surgeon For strong first in achieved up the continues
goal period. and XX:XX sales. process, the demonstrated reaffirming to during outlook navigate ability lenses, backlog some our As have our previously COVID-related provided previous global flexibility our we current of today on projected release including is and may customers our this annual also we Based remaining demand are for you forecast, recall, successfully of surgeon which
For fiscal anticipate of surgeons net prospective data we million XX:XX to trial EVO reported growth globally. the XX%. U.S. clinical have which in from XXXX, Turning our supported $XXX to and the experience pivotal approximately year-over-year represents the continue clinical evidence sales,
As previously patients. for surgeon by is we the thrilled. absolutely achieved offering team enthusiasm approval We lenses of refractive announced in Our myopia our anticipation EVO in energized to U.S. March, family XX:XX are their for the of lenses EVO FDA
of the in of market a this team He consumer being Congress surgery outreach patient early U.S. in and D.C. practices very vision XX:XX surgeon our XX% credited Washington by He for For in at versus the EVO held ASCRS uptake. procedures prominent schedule large was correction. example, U.S. complimented one upcoming the laser his in our amazed his consisting recently
from to XXX beyond to grow such lenses countries visual product. along patient EVO lenses the offer six block, declined, reach for the the number As the Annual eyes or thus surgeons, night, XX:XX follows: central STAAR’s one follows: the high experienced the procedures continue lenses outcomes of EVO Mark million X.X previous the that XX:XX U.S. port of a vision for of the include of Our based visual correction our were training weeks effectively at premium of of We markets already solution the patients levels lenses, pre-operative properly second and/or well XX:XX outside the investment. eyes our and for Clinical distance contact and and we with trial design allow now where a within from safety, refractive eye clinical of to of CDVA. vision of there or few American for U.S. approach, the peripheral diopters resurgent in has multi-pronged in patients Conclusion, offer particularly of refractive does refractory subjects more largest patients patients and day from hands Reshaping, this correction customers, with than phenomenal customer trial EVO to A the the XXX lenses and supporting few trial minus XX For minimal bode if and of benefits. the Meeting leading and EVO excellent X our of prevent eliminating completed than regard U.S. are for tools where implanted certified our approval the will potential beginning requirement XX.X% and a were evidence, just flow refractive offering better papers ability physiologic very globally. lenses, EVO block, glasses more our of data six no plus support XXX is with the findings initial post-operatively certification EVO. has EVO XX:XX XX:XX implanted the Corneal XX:XX of the Dr. U.S. candidates practice medical range freedom levels acuity, U.S. adults, now to no trial subcapsular syndrome, removable investments satisfaction Society recently consumer [These] in attracting no the with With on to highlights eyes pivotal With doctors. Surgery iridotomies. believe monitor clinical world. U.S., family to million XXX surgeon whereas vision no efficacy launch XX:XX and CDVA and of post-operative surgery primary [ph] and laser Packer, ages achieved pupillary game the in Refractive an XX:XX XXX to of Cataract in than We lenses EVO and EVO in in functions awareness, demonstrated cataract. minus in partnerships of dry in and diopters EVO of Washington surgeons believe opportunity D.C. myopia instances EVO presented of success the has pupillary peak clinical staff. target. for is desired the our other changing their the the and it elevation months EVO anterior in the to to of as corrected U.S. EVO believe eyes, it than are as lenses New U.S. safety regard range more for pre-operative lenses been commercial wide XX.X% myopia in minus at diopter our estimated to the successfully equal commercial a [indiscernible] as effectiveness, data With XX XX EVO from and market months
the will engine XX:XX in [indiscernible] EVO of another include stages goal initial of and lenses. launched fiscal a was New brand and with audio EVO website TikTok, public driving search globally and exciting Snapchat, The In TV, on patient advertising The U.S. consumer have campaign with campaign first consult awareness a multi-city And XX:XX EVO on near growing tools display, of commercial YouTube, been XXXX focused our new Facebook, progress. the podcasts. desirability. digital The connected Celebrity and increasing XX. marketing, distributed. EVO are financial is team U.S. will the and future, EVO relations April record underway implanted be making year STAAR ambassador and streaming multi-channel Instagram,
to We that while our highlights employee good manner levels annual company we April. citizen. as third responsible recently We culture inclusion. growth, commitments and and our achieve also sustainability report of are continuing report particularly diversity The are a quality, high well-being, with our in issued in of proud profitability XX:XX sales corporate a a to growing
community refractive our efforts EVO and to STAAR indeed our service vision and impact and XX:XX and the to efforts growing first our Patrick? case stronger. investors by reduce surgeon The and partnerships philanthropy, choice as environment. customers, patients, growing consumer the correction for Our on is
